jueves, junio 02, 2005

Better living through microbes

from Nature Biotechnology
Monya Baker
San Francisco


Genetically engineered bacteria made biotech drugs possible. Now, they are becoming drugs in their own right, Monya Baker reports.

On April 30 this year, two Florida patients received a unique mouth rinse. Using a cotton swab, a dentist painted billions of genetically modified live bacteria of the species Streptococcus mutans onto their pearly whites. If all goes as planned, these bacteria, which lack the gene to make enamel-eroding lactic acid, will replace their naturally occurring, acid-making counterparts, which cause tooth decay.

Besides S. mutans, a number of strains of live bacteria are being developed as therapies. A Lactococcus Lactis strain, engineered to secrete a therapeutic protein, has already been tested in patients with Crohn disease at the University of Amsterdam; in April, trial results were submitted for publication. Also that month, Osel of Santa Clara, California, began phase 2 trials using a proprietary, naturally occurring strain of live Lactobacillus crispatus to treat recurrent urinary tract infection and recurrent bacterial vaginosis. Other academics and companies are exploring genetically modified bacteria against cancer and infectious diseases.
As drugs, bacteria offer several advantages: compared with therapeutic proteins, they are easier to grow, purify and store; although engineering them to express (or not express) a particular gene takes expertise, it needs to be done only once. But along with their convenience and versatility, bacteria reproduce and evolve, making them hard to predict. That creates tricky regulatory issues, and most investors are keeping their distance. But even without venture backing, the field is progressing steadily through the clinic.

Living therapies
The first dose of engineered S. mutans comes two years after the US Food and Drug Administration (FDA) placed Alachua, Florida-based Oragenics' clinical trial on hold for safety concerns. The current seven-day trial requires bacteria with additional engineering. The gene for alanine racemase is deleted, which makes the bacteria dependent on D-alanine for their growth. During the clinical trial, they are supplied with the nutrient in a mouth rinse applied twice-daily. And, just in case the bacteria must be eliminated quickly, all patients enrolled in the trial must wear dentures, which can be removed should problems arise. When the trial is over, patients will rinse their mouths with an antibiotic and be monitored, along with their spouses, for three months.

Oragenics hopes that eventually the bacteria will become a routine part of dentistry, a one-time treatment applied to children's teeth before they start getting cavities. CEO Chuck Soponis acknowledges no one has any specific idea what ill health effects the bacteria might cause. The strain does not make a recombinant protein or displace other species of bacteria living on the tongue and gums. Still, he says, the FDA is right to be cautious. “You're putting a genetically modified bacteria that's going to be in people's mouths for a lifetime, and that hasn't been done before.”

Using live bacteria, or probiotics, to promote health is already common in Japan and becoming increasingly so in Europe. In fact, about 30 probiotic prescription products are sold in Japan. Far more common are products sold without prescriptions as so-called functional foods. The Japanese company Yakult Honsha of Tokyo sells 25 million bottles a day of a fermented milk drink, each one boasting that it contains 8 billion live Lactobacillus casei strain Shirota, which allegedly make for a more healthful gut flora. However, the efficacy of these over-the-counter products is uncertain, and they can't command the high prices of prescription drugs.

Investors hang back
In general, companies seeking funding for live bacteria therapies will have an even harder time finding funding than other biotechnology startups, according to Irena Melnikova, research manager at consulting firm Life Sciences Insights of Framingham, Massachusetts. “This is something very novel,” she says, “and when you start talking about putting live bacteria in humans, there's a negative first reaction.”

In fact, neither Oragenics nor Osel are accessing traditional venture capital (VC) sources to fund their programs. Oragenics went straight to the public markets, listing the company on the Toronto Venture Exchange in June 2003, and moving it to the American Stock Exchange in May last year. Though Osel began in 1998 with money from the founders and has received funding from government agencies including the National Institutes of Health, it has relied mainly on private investors who are not venture capitalists, according to the company's president Ralph Levy. “The VC community does not have a model which our product fits into,” he says. “Small molecules and antibodies, they've seen that; live bacteria they don't understand.”

Oragenics is also pursuing an antibiotic and an over-the-counter probiotic, both stemming from research by the company's CSO and cofounder Jeff Hillman. The probiotic is a proprietary mixture of three naturally occurring bacteria expected to prevent periodontal disease when taken daily. Oragenics plans to partner with larger oral care companies and get the product on the market in Europe and Asia sometime next year and use revenues from probiotics sales to partly finance development of its genetically modified bacteria, which will be marketed as a prescription drug administered by dentists.

Osel's Levy is quick to distance himself from the nonprescription marketplace. He doesn't even like the term 'probiotic.' “The easy route is just manufacturing it and putting it in a store. My market is the physician who's going to write a script to treat a patient,” he says. Levy thinks venture capitalists will be more forthcoming with funding once phase 2 results are available. “When we have the data, they'll be where I need them to be.”

Producing drugs in situ
As an academic, Lothar Steidler, a molecular biologist at Cork University in Ireland, bypassed many corporate headaches while still moving a live bacteria therapy into clinical trials. The work began about ten years ago when Steidler, then at Belgium's Ghent University, was looking for an inexpensive source of cytokines—soluble protein regulators of the immune system. Steidler and his colleagues acquired all sorts of expression systems to make cytokines in-house, and routinely scanned the literature for more. “We bumped into Lactococcus because I met someone at a conference and he had a nice poster,” says Steidler, who eventually created Lactococcus that secreted human interleukins 2, 6 and 10 (IL-2, IL-6, IL-10) as well as trefoil factors. As a production system the bug was disappointing; its output was a hundredth to a thousandth that of Escherichia coli, says Steidler. “But what immediately struck our minds was that the product was soluble and was fully biologically active.” Most cytokines do not require glycosylation to be active, and so don't need to be made in eukaryotic cells. In Lactococcus cultures, soluble cytokines could be recovered from the supernatant with its secretion leader clipped off correctly. In other words, says Steidler, “The material you got for IL-10 was indistinguishable from the eukaryotic product.” Furthermore, people have safely eaten Lactococcus in cheese and yogurt for thousands of years. Perhaps, Steidler's team thought, patients could safely consume it as a drug.

The technology seemed especially applicable to inflammatory bowel disease, in which the immune system erroneously attacks the gut, causing chronic discomfort and frequent diarrhea. IL-10 tends to quiet the immune system, but administering the cytokine orally is problematic, as its activity is rapidly destroyed by acid in the stomach. Given intravenously, the cytokine spreads through the entire body, where it can actually rouse the immune system. But Lactococcus taken by mouth could travel through the stomach and secrete IL-10 exactly where it was needed, along the intestinal wall. “We're still surprised at the simplicity,” says Steidler. In two separate mouse models of colitis, treatment with the bacteria either prevented disease onset or dramatically reduced its severity1. The mice suffered no obvious adverse effects.
In an unusual move, the University of Amsterdam approached Steidler about putting the bacteria into clinical trials. But the therapy was not ready for people yet. “You can't just release genetically modified bacteria in the environment without precaution,” says Steidler. The research team needed a way to prevent the engineered bacteria from growing outside the body, so they decided to insert IL-10 into the locus normally occupied by the gene for thymidylate synthase2, which is essential for DNA synthesis, and hence required for growth.

The modified Lactococcus can readily absorb thymidine from the nutrient-rich gut, but quickly depletes any available in the environment; its viability decreases about a millionfold within 60 hours after the source of thymidine is removed.
To obtain permission to run trials in Holland, explains Steidler, researchers must publish trial plans in newspapers and the Royal National Library in The Hague. That way the general public can question trials before they start. However, no one raised concerns during that process, he says. Although that may seem surprising, given widespread objection to genetically modified food in Europe, attitudes toward transgenic plants do not predict attitudes toward transgenic therapies.

The technology is currently covered under 45 patents owned by Flanders Inter university Institute for Biotechnology (VIB) of Zwijnaarde, Belgium, which is working with Steidler to commercialize the technology. VIB director Rudy Dekeyser says the group is looking both at corporate partners to collaborate on clinical development, as well as venture capitalists to start a new company.

But even if the technology finds corporate backing, that doesn't mean that other companies developing live bacteria will necessarily have an easier time, says IDC's Melnikova, “It's always hard to be the first, but each individual therapy will be considered on its individual merits.”

Bacteria take on cancer
Several groups are looking for ways to use microbes against cancer, and in fact, the naturally occurring bacteria, bacillus Calmette-Guerin, is standard therapy for a type of bladder cancer. Still most work in this area uses viruses rather than bacteria. Viruses had a head start because they can target specific cells, according to David Bermudes, director of microbiology at Vion in New Haven, Connecticut. Still, he says, bacteria offer several practical advantages. “A virus depends on the cell to deliver its payload. Bacteria are self-contained factories.” Moreover, bacteria can carry more genetic material, be controlled with antibiotics and “are a joy to manufacture compared with viruses.”

Vion has already taken a cancer-fighting bacteria through three phase 1 trials. It chose bacteria for their ability to grow preferentially in tumors, an advantage that molecular biologists were slow to recognize, says Bermudes. The company's genetically modified Salmonella typhimurium makes cancer drugs potent at the site of the tumor, allowing a less toxic prodrug to be administered. As it grows in tumors, the engineered S. typhimurium expresses an E. coli enzyme for cytidine deaminase, which converts nontoxic 5-fluorocytosine (5-FC) to the anticancer drug 5-fluorouracil (5-FU)3. In mouse studies, the treatment, called TAPET-CD, slowed tumor growth by as much as 95%.

In mice, the bacterium also has some ability to target tumor cells even without cytidine deaminase. Vion tested versions of S. typhimurium lacking the enzyme in phase 1 trials and found that although the bacteria found their way to tumors, the therapy had no antitumor activity. “It was a commercial failure, but a scientific success because you've shown that you can make a bacteria that's safe for systemic administration that targets tumors,” says Bermudes. Human trials with TAPET-CD showed conversion of 5-FC to 5-FU in two of three patients, but were stopped for what Bermudes calls “nonmedical reasons.” Vion is focusing efforts on a small molecule anticancer drug now in phase 2 trials.

Cerus of Concord, California, looked at both viral and bacterial vectors before deciding to engineer Listeria monocytogenes as a cancer vaccine. As one of the deadliest food-borne bacteria, it seems a surprising choice for a vaccine vector, but microbiologists have a long history of finding ways to attenuate pathogens, and L. monocytogenes had key advantages, according to Tom Dubensky, head of vaccine development at Cerus. The bacteria is easy to grow and elicits a potent immune response. Also, unlike many other microbes, it is not neutralized by antibodies, so repeated vaccinations are more likely to be effective. In fact, a clinical trial of 20 healthy volunteers showed that a genetically attenuated strain of L. monocytogenes could still prompt an immune response without serious side effects.

Wild-type L. monocytogenes enters liver cells and spreads from cell to cell by sending bacteria-filled protrusions into neighboring cells, thus avoiding the immune system. Cerus's engineered bacteria lack this ability, but they can still enter antigen-presenting cells and stimulate an immune response4. Although Cerus's first-generation L. monocytogenes works by boosting only innate immunity, researchers have also created a way to stimulate adaptive immunity. “We spent a lot of time learning how to program L. monocytogenes to secrete antigen from the bacterium within the antigen-presenting cell,” recalls Dubensky. The next-generation of L. monocytogenes vectors make mesothelin, a tumor marker present in many ovarian and prostate cancers; Cerus has a joint project with MedImmune of Gaithersburg, Maryland, using its proprietary EphsA2 antigen as well. Cerus hopes to file an investigational new drug application by the end of this year for its first-generation L. monocytogenes against colorectal cancer that has metastasized to the liver. Dubensky expects close scrutiny from the FDA but thinks that for cancer patients that have not benefited from other therapies, the risk-benefit calculations favor experimental therapies. “While there is risk to being the first use in man, these are people for whom there are no other options.”

Bert Vogelstein, an oncologist at Johns Hopkins University in Baltimore, uses a version of Clostridium novyi that lacks the gene to make -toxin. This spore-forming bacteria germinates in oxygen-poor tumors and turns them to mush within18 hours. Ruptured cells from the dying tumor prompt an immune response that trains the immune system to attack remaining cancer cells5. The therapy has been tried in mice, rats, and rabbits; in one in three animals the tumor is destroyed without additional drugs. Odds of vanquishing the tumor improve if anticancer drugs are given as well. Vogelstein thinks the therapy is promising, but is adamant that it is not ready to be tested in humans. Toxicities so far seem acceptable, he says, but the immune response elicited can be so strong that it harms the host.

Cautious yet optimistic
Whether liquifying tumors or pushing out harmful bacteria, live-bacteria therapies can exploit mechanisms impossible for small molecule and protein drugs, and can even be engineered to deliver drugs where the body needs them. But for all this, they present unpredictable and unquantifiable risks. As Vogelstein says, “The agent is new and it's self-replicating. The dose that we give and the dose that we get are not the same.” Vion's Bermudes says skepticism is warranted, but so is hope, particularly for patients who have no other options. “Ten years ago, everybody said antibody therapies don't work. Where are the products? Now there are almost twenty products on the market.”

References
Steidler, L. et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 289, 1352–1355 (2000).
Steidler, L. et al. Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10. Nat. Biotechnol. 21, 1785–1789 (2003).
Nemunaitis, J. et al. Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients. Cancer Gene Ther. 10, 737–744 (2003).
Brockstedt, D.G. et al. L. monocytogenes-based cancer vaccines that segregate immunogenicity from toxicity. Proc. Natl. Acad. Sci. USA 101, 13832–13837 (2004).
Agrawal, N. et al. Bacteriolytic therapy can generate a potent immune response against experimental tumors. Proc. Natl. Acad. Sci. USA 101, 15172–15177 (2004).

sábado, mayo 14, 2005

Yoghurt -- part one

FoodInfo Online Features -->12 May 2005

In the first part of a two-part series,
Ernest Mann rounds up the most recent literature relating to yoghurt.

If proof was needed that there is increasing world-wide interest in yoghurt and related fermented milk products, this two part review of recent literature on the subject, covering reports from no less than 21 countries from all parts of the world, will surely provide it.
The proceedings of the International Dairy Federation (IDF) symposium on Aroma and Texture of Fermented Milk, held in Denmark in 2002 (1) provide an excellent starting point.
Following an introductory review of the applications of fermentation technology there were sessions on cultures, processing and product evaluation as well as nine poster presentations.
Among several reviews covering different aspects of yoghurt is a recent one published in this journal (2) dealing with the development of yoghurt and dairy dessert products with improved nutritional and health promoting properties.
The development of structure in fermented dairy products and ways of controlling their textural properties has been discussed and reviewed in a paper published in the International Journal of Dairy Technology (3).
The effects of different factors, including milk components, starters and manufacturing and handling processes on yoghurt texture, as well as methods for assessing texture, have been reviewed in the USA (4). A comparative assessment of the market for plain and fruit flavoured yoghurts in Europe (5) showed that, whereas the annual per capita consumption of plain yoghurt in 15 European countries averaged 3.7 kg (ranging from 0.30 kg in the UK to 13.95 kg in the Netherlands), that of fruit flavoured yoghurt averaged 8.86 kg (ranging from 3.10 kg in Hungary to 21.8 kg in Finland). Recent developments in the manufacture and properties of the Egyptian yoghurt, zabady, have been reviewed (6).
The first of several papers on microbiological aspects of yoghurt comes from France (7) and examines the interactions between Streptococcus thermophilus and Lactobacillus delbrueckii subsp. bulgaricus when they are co-cultured, as in the production of yoghurt.
Strains Belgian scientists (8) have examined the use of exopolysaccharide (EPS) producing strains of S. thermophilus as starter cultures in the production of products such as yoghurt. Italian workers (9) have compared the properties of 17 strains of S. thermophilus for the production of yoghurt.
The results indicate great differences in characteristics between different strains affecting the nature and quality of the yoghurt.
In Sweden (10) the functional properties of yoghurts produced with EPS producing strains and non-producing strains of S. thermophilus and L. delbrueckii subsp. bulgaricus have been screened and correlations between sensory and rheological properties investigated.
Chinese workers (11) have also studied the use of EPS producing yoghurt cultures with a view to improving the sensory and rheological properties of yoghurt. Three bacteriophage-sensitive strains of L. delbrueckii subsp. bulgaricus isolated from commercial yoghurt starters in Argentina (12a) and their indigenous bacteriophages, have been characterised with regard to the phage absorption process.
Scientists in Bulgaria (12b) have isolated strains of yoghurt cultures from home-made yoghurts in the mountain regions of Bulgaria, with a view to identifying new strains suitable for the production of improved quality yoghurts under industrial manufacturing conditions.
Several reports in the probiotic yoghurt sector are headed by one (13) on developments in the probiotic yoghurt market in Japan where, apart from the well-established Yakult, several new products have been launched in recent years.
Also reported (14) is the launch of a range of new probiotic yoghurt products in Slovenia using Bifidobacterium lactis HN019, a new culture produced by Danisco under the HOWARU name. Animal trials with this culture have demonstrated improved immune function response. Scientists in the Ukraine (15) have reported studies on the biotechnological parameters of yoghurt and kefir during which the probiotic properties of these products were confirmed in clinical trials.
Croatian researchers (16) have studied the aroma of probiotic yoghurts with and without supplements, with special reference to changes in aroma compounds occurring during storage as a function of time and temperature. Bifidobacterium lactis HN019, referred to above, has been described in greater detail (17) with regards to its immunity-enhancing properties and its inhibitory effects on gastrointestinal pathogens.
In Italy the production of probiotic yoghurt with increased levels of bioactive peptides has been investigated (18). Australian scientists (19) have reported studies on the effects of packaging materials and dissolved oxygen on the survival of probiotic bacteria in yoghurt.
The results suggest that, although the level of dissolved oxygen in yoghurt can be influenced by the type of packaging material, it is unlikely to affect the survival of probiotic bacteria in yoghurt. The effects of chicory fructooligosaccharides on the viability of yoghurt starter cultures and two strains of Bifidobacterium during refrigerated storage have been studied in Turkey (20). German dairy Onken has launched a new range of 1.5% fat functional yoghurts including flavours such as aloe vera and cherry, juniper and acerola mix (21). In Germany, Müller has introduced a coffee-flavoured yoghurt with a separate serving of amarettini biscuits in their dual compartment range. In Switzerland, Unilever has extended its pro.activ line of functional, cholesterol-lowering products with a mocca-flavoured yoghurt (22).
New yoghurts containing antioxidant ingredients have been introduced in Japan (23). Glico Dairy Products sells a probiotic yoghurt containing Bifidobacterium spp., whole blueberries (a source of antioxidant polyphenols) and a mixture of fruit juices. Ice cream yoghurt An ice cream yoghurt made with a live starter culture mixture capable of producing EPS during fermentation, gives improved texture and viscosity and (24) is covered by a European patent. Korean scientists (25) have reported that feeding ovariectomised rats with safflower seed yoghurt results in significant improvements in bone health, providing a protective effect against osteoporosis. The cholesterol-lowering ability of isolated soya proteins incorporated into yoghurt and fed to human subjects was confirmed in a Finnish study (26).
A Nigerian scientist (27) has reported good results from trials in which cashew apple was incorporated into yoghurt, with no adverse effects on composition or sensory quality.
A Chinese worker (28) has reported results from a trial in which Siraitia grosvenorii was added to yoghurt. The product satisfies consumer expectations for palatability, low sugar content and low energy value. Also reported from China (29) is a study on the optimum processing conditions for producing pollen yoghurt. Another Chinese team (30) has reported on the production of a blood sugar-reducing yoghurt for diabetics.
The production of salted yoghurt from set and torba yoghurts has been investigated in Turkey (31), with salted yoghurt produced by cooking for 30 minutes being the most preferable according to sensory tests. Among a number of enriched yoghurt products described are those enriched with rice starch (32) whose physical and sensory properties, together with a good low temperature stability, make it a very good texturiser for low-fat yoghurts.
Egyptian scientists have reported (33) that the replacement of up to 40% of dried skim-milk with a modified starch in yoghurt had no adverse effects on the sensory quality of the yoghurt. A PCT patent (34) covers a stirred type of yoghurt product incorporating chocolate or other confectionery pieces. Fortified milk A Turkish study (35) shows the effects on physicochemical properties, sensory properties and composition of methods used for the fortification of milk for yoghurt manufacture. Several of the additives had a significant effect on the sensory and other properties of the yoghurts.
The calcium fortification of yoghurt is covered in a US patent (36), as well as in work reported from Egypt (37) from which it was concluded that fortification of milk with calcium phosphate at levels of ≤90mg per 100ml leads to an acceptable product with high calcium content.
Product and process for magnesium enrichment of yoghurt to levels of up to 3 000mg per litre are covered in a European patent (38). An improved process for the production of a high viscosity stirred yoghurt is claimed in a PCT patent (39). A Croatian scientist (40) has described studies on the rheological properties of stirred yoghurt during long-term storage at 4 and 8ºC, using the dynamic oscillation method. Among the findings were that rheological properties were influenced by the addition of dried whole milk or whey protein.
Finally, the first of two reports from China (41) indicates that the addition of denatured starch in the manufacture of stirred yoghurt increased the viscosity as well as the stability of the yoghurt to heating, acidity and shearing stress. In the second study (42), different stabilisers were compared in the manufacture of stirred yoghurt in order to improve overall quality, texture and flavour.
(1) Internat Dairy Fed (2003) Proc Symp Fermented milks Kolding, Denmark 2002
(2) McKinley, M (2004) Dairy Inds Internat 69(4)32
(3) Lucey, J (2004) Internat J Dairy Technol 57(2-3)77
(4) Sodini, I et al (2004) Critic Rev Food Sci & Technol 44(2)113
(5) Anon (2003) Dte Milchwirtsch 54(22)958
(6) Abou-Donia, S A (2004) Egypt J Dairy Sci 32(1)1
(7) Courtin, P et al (2004) Lait 84(1-2)125
(8) De Vuyst, L et al (2003) Proc Symp Fermented Milks Kolding, Denmark 2002
(9) Lavezzari, D et al (2003) Proc Symp Fermented Milks Kolding, Denmark 2002
(10) Folkenberg, D M et al (2003) Proc Symp Fermented Milks Kolding, Denmark 2002
(11) Gu Rui Xia et al (2002) China Dairy Ind. 30(5)5
(12a) Quiberoni, A et al (2004) J Appl Microbiol 95(2)340
(12b) Minkova, S et al (2004) Khranitelno-vkusova Promishlenost No 2
(13) Hayes, D (2004) Dairy Inds Internat 69(7)14
(14) Anon (2004) Dairy Inds Internat 69(9)40
(15) Chagarovsky, V P et al (2003) Microbiol Zhurnal 65(6)67
(16) Hruskar, M et al (2003) Mljekarstvo 53(3)195
(17) Schmid, K et al (2003) Proc Symp Fermented Milks, Kolding Denmark 2002
(18) Chianese, L et al (2003) Proc Symp Fermented Milks, Kolding Denmark 2002
(19) Talwalkar, A et al (2004) Internat J Food Sci & Technol 39(6)605
(20) Alkalin, A S et al (2004) Internat J Food Sci & Technol 39(6)613
(21) Anon (2004) Dairy Inds Internat 69(5)8
(22) Anon (2004) Dairy Inds Internat 69(8)12
(23) Anon (2004) Dairy Inds Internat 69(6)13
(24) Yogurtal Sp A et al (2003) Europ Pat Appl 1,430 785
(25) Kim, K Y et al (2004) J Anim Sci & Technol 46(1)69
(26) Puska, P et al (2004) Brit J Nutrit 91(3)393
(27) Aroyeun, S O (2004) Nutrit & Food Sci 34(1)17
(28) Bu Chun Wen (2004) China Dairy Ind 32(1)35
(29) Zhao Hai Zhi et al (2003) China Dairy Ind 31(2)19
(30) Li Tao (2002) China Dairy Ind 30(5)106
(31) Sahan, N et al (2003) Gida 28(5)545
(32) Potts, A M (2004) Dairy Inds Internat 69(4)31
(33) Kebary, K M K et al (2004) Egypt J Dairy Sci 32(1)111
(34) General Mills. Inc (2003) PCT Pat Appl WO 2004/008867
(35) Guven, M et al (2003) Gida 28(4)429
(36) General Mills Inc et al (2000) US Pat 6 740 344
(37) El-Garawany, G A (2004) Egypt J Dairy Sci 32(1)59
(38) Roujanski, O (2002) Europ Pat Appl 1 385 386
(39) General Mills Inc et al (2003) PCT Pat Appl WO 03/096816
(40) Vilusic, M (2003) Mljekarstvo 53(3)211
(41) Wang Dan et al (2002) China Dairy Ind 30(3)14
(42) Shao Hong et al (2002) China Dairy Ind 30(4)10

This review was originally published in the March 2005 edition of Dairy Industries International

Fuente de la página WEB

viernes, mayo 13, 2005


Kefir – a complex probiotic


Edward R. Farnworth
Food Research and Development Centre, Agriculture and Agri-food Canada, St. Hyacinthe, Quebec, Canada J2S 8E3.

Abstract

Kefir is a fermented milk drink produced by the actions of bacteria and yeasts contained in kefir grains, and is reported to have a unique taste and unique properties. During fermentation, peptides and exopolysaccharides are formed that have been shown to have bioactive properties. Moreover, in vitro and animal trials have shown kefir and its constituents to have anticarcinogenic, antimutagenic, antiviral and antifungal properties.
Although kefir has been produced and consumed in Eastern Europe for a long period of time, few clinical trials are found in the scientific literature to support the health claims attributed to kefir. The large number of microorganisms in kefir, the variety of possible bioactive compounds that could be formed during fermentation, and the long list of reputed benefits of eating kefir make this fermented dairy product a complex probiotic.

11. Conclusions



Many probiotic products have been formulated that contain small numbers of different bacteria. The microbiological and chemical composition of kefir indicates that it is a much more complex probiotic, as the large number of different bacteria and yeast found in it distinguishes it from other probiotic products. Since the yeasts and bacteria present in kefir grains have undergone a long association, theresultant microbial population exhibits many similar characteristics, making isolation and identification of individual species difficult. Many of these microorganisms are only now being identified by using advanced molecular biological techniques. The study of kefir is made more difficult, because it appears that many different sources of kefir grains exist that are being used to produce kefir.

The production of kefir depends on the synergistic interaction of the microflora in kefir grains. During the fermentation process, the yeasts and bacteria in kefir grains produce a variety of ingredients that give kefir its unique taste and texture. After fermentation, the finished kefir product contains many ingredients that are proving to be bioactive. At least one exopolysaccharide has been identified in kefir, although others may be present. Many bacteria found in kefir have been shown to have proteinase activity, and a large number of bioactive peptides has been found in kefir. Furthermore, there is evidence to show that kefir consumption not only affects digestion, but also influences metabolism and immune function in humans.

viernes, diciembre 31, 2004


LA LEVADURA ESTA CRECIENDO

Nature 429, 224 - 225 (2004) doi:10.1038/nj6988-224a

The yeast is rising

Kendall Powell

Kendall Powell is a freelance science writer based in Broomfield, Colorado.

Makers of beer, wine and cheese need microbiologists to keep fermented products at their peak. Kendall Powell gets a taste of the career offerings.

Every student who has ever crossed paths with Saccharomyces cerevisiae, the academic version of brewer's yeast, has pondered getting a job at the local brewery. Cody Reif is living the dream. As a microbiologist at the New Belgium Brewing Company in Fort Collins, Colorado, Reif and his colleagues start each day by tasting the latest batches of the company's eight brews. He says that the group's taste-test gives better statistics for determining if a batch is up to company standards. Yeah, sure, statistics.

"Is working here as much fun as people think? Yes, it is," Reif says. The daily sampling illustrates a criterion for working with fermented food products not usually highlighted in a basic microbiology degree: critical sensory skills. It reflects the fact that the bottom line is not the science behind making fermented products, but rather the flavour and appeal of a product.

Careers focusing on the microbiological processes that go into making beer, wine and dairy products demand solid backgrounds in microbiology and biochemistry, but they also incorporate special expertise in food science and sensory training. Research projects in this small but diverse field range from troubleshooting contaminants that might spoil a vat of wine to designing probiotic microbial cultures for 'functional foods' that aim to improve the immune system.

An understanding of how fermenting microbes behave, and how their metabolites change the properties of foods and beverages, can be picked up in specialist degree programmes or through on-the-job experience. Reif, who has a microbiology degree, brags: "I can probably identify four or five different strains of yeast or bacteria just by smell."

One place a microbiologist might seek work is in a microbrewery — a small regional enterprise. There, says Reif, it is necessary to know the ins and outs of the entire beer-making process because any microbial problems could bleed into the next phase. Also, scientists at smaller companies handle most analyses on site, from quality control and yeast propagation to monitoring for 'critical beer spoilers' — bugs that can crash the keg party.

This holds true at smaller wineries, too, says Lars Bjorkman, an enologist at Flora Springs Winery in St Helena, California. His bachelor's degree in viticulture and enology from the University of California, Davis, combines classic microbiology, biochemistry and food science with sensory classes for the tailored enology half of the degree. These allow him to analyse his winery's varieties through each stage of production. Bjorkman says that a large part of his job is to ask each day, "What is growing in this wine?", and to find out if it is advantageous or a troublemaker.

A Strange Brew
Larger enterprises such as Miller Brewing Company in Milwaukee, Wisconsin, and E. & J. Gallo Winery in Modesto, California, have their own research and development departments that employ scientists at bachelor's, master's and PhD levels. Tom Pugh, director of enology research at Gallo, says that the company does both applied research, to optimize fermentation conditions, and basic research that strives to identify the microbial characteristics that affect a wine's feel, flavour and aroma.

His research group looks at the way genetic differences between strains affect metabolism throughout the fermentation. Gallo also takes on microbiologists with degrees slanted towards wine-making as winemakers, he says, overseeing a wine's production from grape to bottle.

Similarly, David Ryder, chief brewmaster at Miller, says that microbiologists may want to become brewmasters at individual breweries. There's also a small group of microbiologists doing R&D at the corporate headquarters in Milwaukee. These, says Ryder, track yeast physiology and use DNA microarrays to find out if the yeast strains are 'happy'. Happy yeast are healthy yeast that grow fast in a variety of environments and efficiently convert sugars to alcohol. Like Pugh, Ryder stresses that he looks for employees who are passionate about both the science and the product.

Cheese Whizzes
And what goes better after a fine wine than a nice hard cheese to cleanse the palate? Makers of cheese (and yoghurt) face an equally complex, though different, fermentation process. Microbiologists working on the dairy side of the fence also hunt for the microbes that bring the desired texture, flavour and aroma to fermented milk. Understanding how microbes will react under the different stresses of the cheese-making process is a key component not necessarily gleaned from working in an academic microbiology lab. This is where the practical side of a food-science degree comes in, says Kayla Polzin, a senior scientist and microbiologist at the Land O'Lakes dairy company's labs in Arden Hills, Minnesota.

Polzin says that, in her job, a deep understanding of microbiology and metabolism is just as important as a broad understanding of the many microbes that can crop up in dairy cultures. She is one of two PhD-level microbiologists at Land O'Lakes, but many more dairy-food microbiologists are employed by the companies that provide the starter cultures. As well as developing cultures that are resistant to bacteriophages and viruses, or that work more efficiently, these scientists track down microbe characteristics responsible for specific flavours and textures sought by their customers.

"Pizza companies can be very, very demanding as to what the cheese looks like on their pizza. It has to brown, stretch and melt just the right way," says Dennis Romero, a molecular microbiologist at the starter-culture company Rhodia in Madison, Wisconsin. He is one of about two dozen research scientists at Rhodia, but he notes that most of its competitors are based in Europe and are ten times as large.

Romero stresses that researchers at starter-culture companies must do science that is practical at all times. The best way for microbiology students to gain this applied viewpoint of research, he says, is to work on an industry-funded collaboration. Starter-culture companies tend to 'outsource' the most basic research by setting up joint projects with an academic lab.

Christian Hansen, a food-ingredient company based in Hoersholm, Denmark, employs about 80 scientists in its central research laboratories. Chief science officer Peter Olesen says that — because the company deals in colours, flavours and enzymes as well as cultures — it employs protein chemists, chemical engineers and scientists with medical and veterinary degrees (see Gut feeling for health).

One of their recent basic microbiology research projects developed what Olesen calls a "revolution in lactic acid bacteria" — a strain engineered so that it can grow under aerobic conditions (with oxygen), resulting in cultures that ferment faster.

All areas of food microbiology value knowledge of food processes and fermentations more than a narrow focus on molecular mechanisms of organisms. For that reason, most of the opportunities in this field do not require postdoctoral training. Industry-related experience is rated highly — whether an internship, working on a wine harvest or an industrial collaboration.

Reif says that, all beer-drinking benefits aside, he gets job satisfaction from the critical thinking required in troubleshooting: "When problems come up it's an opportunity to use your head."

Top

Story from news@nature.com:

http://news.nature.com//news/2004/040510/nj6988-224a.html

sábado, octubre 09, 2004

How viable are probiotic bacteria in yoghurts?

Foodinfo Online FSTA Reports -->8 October 2004

Probiotic bacteria such as Lactobacillus acidophilus and Bifidobacterium spp. have numerous health benefits, which have lead to their incorporation into dairy foods such as yoghurts. However, for probiotic bacteria to be therapeutically effective, a minimum viable count of 106 to 107 cfu/g of these bacteria is necessary.
Standards introduced by food authorities worldwide have encouraged manufacturers to guarantee adequate viability of these bacteria throughout product shelf life. However, several recent market surveys have indicated a steady decline in counts of L. acidophilus and Bifidobacterium spp. throughout the shelf life of probiotic yoghurts. Oxygen toxicity is considered a significant factor in influencing the viability of these probiotic bacteria in yoghurts.
The agitation and mixing steps during manufacture can incorporate high amounts of oxygen into the product. In addition, during storage, oxygen can diffuse into yoghurt through the high-impact polystyrene (HIPS) packaging. As a result, polystyrene-based gas barrier packaging and active packaging films have been developed. A study by Talwalkar et al.1 investigated the effects of packaging materials on the dissolved oxygen content and survival of the probiotic bacteria, L. acidophilus and Bifidobacterium spp., in yoghurt stored at 4--6°C for 42 days. The yoghurts were packaged in oxygen-permeable HIPS, oxygen-barrier material (Nupak) and Nupak with an oxygen-scavenging film (Zero2).
No significant decreases were observed in bacterial viability of any of the yoghurts tested, suggesting that oxygen alone is not a significant factor in causing poor viability of these bacteria in yoghurt.
---------------------------------------------------------------------------------
1 Talwalkar, A; Miller, CW; Kailasapathy, K; Nguyen, MH (2004).
Effect of packaging materials and dissolved oxygen on the survival of probiotic bacteria in yoghurt. International Journal of Food Science and Technology 39 (6) 605-611.

AN: 2004-09-Pl1566
TI:
Effect of packaging materials and dissolved oxygen on the survival of probiotic bacteria in yoghurt.
DA:
7-May-2004
DT:
Journal Article
AU:
Talwalkar, A.; Miller, C. W.; Kailasapathy, K.; Nguyen, M. H.
PY:
2004
AD:
Correspondence (Reprint) address, K. Kailasapathy, Cent. for Advanced Food Res., UWS, Locked Bag 1797, NSW 1797, Australia.
SO:
International Journal of Food Science & Technology 39 (6) 605–611
RF:
22 ref.
LA:
English
SN:
0950-5423
AB:
Oxygen toxicity has been suggested to be a significant factor influencing the viability of probiotic bacteria, such as Lactobacillus acidophilus and Bifidobacterium spp., in yoghurts. Along with manufacturing steps (particularly agitation and mixing), which incorporate high amounts of oxygen into the yoghurt, the packaging materials used may also affect the level of oxygen diffusing into the product. This study investigated the effects of packaging materials having different oxygen permeabilities on the levels of dissolved oxygen and survival of the probiotic bacteria in yoghurt. Oxygen adapted and non-oxygen adapted strains of L. acidophilus and Bifidobacterium spp. were incorporated in yoghurts, which were packaged in oxygen permeable high-impact polystyrene (HIPS), oxygen-barrier material (NupakTM) and NupakTM with an oxygen scavenging film (Zero2TM). Results showed that, during storage, the level of dissolved oxygen increased steadily in HIPS packaged yoghurt, but remained low in yoghurts packaged in NupakTM and Zero2TM. In all yoghurts, no significant decreases were observed in the viability of either oxygen adapted or non-oxygen adapted cells of L. acidophilus and Bifidobacterium spp. It is suggested that, although the level of dissolved oxygen in yoghurt can be influenced by the type of packaging material, it may not affect the survival of probiotic bacteria in yoghurts.
SC:
Milk and dairy products
KW:
BIFIDOBACTERIUM; INHIBITION; LACTOBACILLUS; LACTOBACILLUS ACIDOPHILUS; MICROORGANISMS; OXYGEN; PACKAGING MATERIALS; PERMEABILITY; PROBIOTIC BACTERIA; YOGHURT

sábado, agosto 07, 2004

Yoghurt - part two

FoodInfo Online Features -->6 August 2004

In the second part of his review,
Ernest Mann concentrates on the scientific aspects of yoghurt production.

The second part of this review concentrates predominantly on more scientific aspects of yoghurt production. A recent study in Australia (30) looked at seasonal variations in physical characteristics of both set and stirred yoghurts. The effects of variations in solids-not-fat contents (10–14 per cent) on gel strengths, whey drainage and other properties were examined. It was found that standardisation of total solids content with dried skim milk was not sufficient to produce yoghurts with consistent physical characteristics throughout a season.
Another group of Australian scientists (31) studied the effects of fortification of milk with two per cent of either whey powder (WP), skim milk powder (SMP) or whey protein concentrate (WPC) on composition, pH, firmness, viscosity, syneresis and microstructure of yoghurt. The results indicated that WP and SMP supplementation reduced viscosity and firmness, while WPC supplementation increased these values.
Another report from the same laboratory (32) looks at the effects of adding proteolytic strains of Lactobacillus delbrueckii subspecies bulgaricus to commercial ABT starter cultures or a mixed starter on the texture of yoghurt and the effects on the survival of starter bacteria. Amongst other things, the results indicated that the viability of probiotic bacteria improved in yoghurt made with the mixed starter with the added Lactobacillus delbrueckii strain.
In the USA, researchers have reported (33) on the effects of stirred yoghurt thickness, flavour and colour on the sensory perceptions of 120 school children. A German study (34a) has reported on the enzymatic cross-linking of milk proteins on the functional properties of set-type yoghurt, involving transglutaminase treatment of milk prior to fermentation with a starter culture. The results indicated that, while the aroma and consistency of yoghurts from enzyme-treated milk were less 'yoghurt specific', they were more creamy than those produced from untreated milk. This suggests that a transglutaminase treatment may simulate fat in fermented products.
The effect of fermentation temperature between 37 and 46°C on the formation and rheology of yoghurt has been studied in the UK (34b) using reconstituted skim milk preheated and fermented with either a ropy or non-ropy starter culture. A study in Spain (35) investigated the effects of manothermosonication treatment (MTS) of milk on the rheological properties of yoghurt made from MTS milk. The results indicated that MTS treatment, which is the simultaneous application of heat and ultrasound under moderate pressure, could result in yoghurts with rheological properties superior to those found in control yoghurts made from untreated milk.
Studies in the USA (36) have compared yield stress, microstructure, shear values and water holding capacity (WHC) in full fat set yoghurt prepared from fortified milk. This had been subjected to either thermal processing (85°C for 35 minutes) or high hydrostatic pressure processing (193 or 676 MPa for 5 or 30 minutes). Amongst other things, the results indicated that yoghurts made from milk treated at 193 MPa and untreated milk (control) exhibited low yield stress, low WHC and large clusters of coalesced micelles. In a more general article (37) on the effects of different ingredients and manufacturing processes on the texture of set, stirred and probiotic yoghurts, the costs of various commercially available yoghurt texturisers are also considered.
An Austrian study (38) on the influence of starter culture on the relationship between dry matter content and the physical properties of stirred yoghurt formed part of an EU project that aimed to develop a standard procedure for the laboratory-scale production of set-type and stirred yoghurt. The first of three reports from the USA (39) was concerned with the evaluation of the textural properties of two types of yoghurt (light or blended), using a trained sensory analysis panel and an instrumental compression/penetration test in combination with a novel data analysis method.
The second report (40) presented a comparison of the effects of aspartame and sucrose on the microstructure of yoghurt. The third study from the USA (41) reports the development of a method for manufacturing a milk protein powder rich in both casein and whey proteins, as well as being free of lactose. The powder was used successfully in the manufacture of non-fat yoghurts without the addition of gelling and stabilising agents. Russian workers (42) have developed a stabiliser for heat-treated yoghurt which is based on a modified maize starch and a texturising agent containing guar gum, xanthan gum and pectin.
The synthesis and utilisation of folate by 32 strains of yoghurt starter cultures and probiotic cultures was examined by Australian scientists (43). Brazilian workers (44) conducted a study of composition and sensory quality of whole stirred yoghurt made from milks with somatic cell counts ranging from below 400 000 to above 800 000 cells per ml. Cell counts higher than 400 000 per ml had a detrimental effect on the sensory quality of yoghurt. A report from Egypt (45) looked at the utilisation of laboratory produced xanthan gum in the manufacture of natural and soya yoghurt. It concluded that the highest sensory scores were obtained when xanthan gum additions of 0.01 and 0.005 per cent were employed with the two types of yoghurt respectively. Acetaldehyde is regarded as a major indicator of flavour in yoghurt.
In a recent Turkish study (46), the effects on acetaldehyde levels in yoghurts, of the use of viscous and non-viscous cultures plus amino acids, treatment with ß-galactosidase and the use of heat-shocked cultures were investigated. The results indicated that the highest acetaldehyde levels in yoghurt were obtained when non-viscous starter cultures were used alone.
The effects of processing and refrigerated storage on the distribution and stability of aflatoxin M1 in yoghurt, artificially contaminated with different levels of the toxin, has been investigated in Greece (47). Spanish scientists (48) have developed a new multiresidue method for determining trace amounts of organochlorine pesticides and polychlorinated biphenyls in yoghurt, the method proving quick, accurate and repeatable. In another Spanish study (49) the survival of E. coli 0157:H7 in yoghurt at different storage temperatures (4–22°C) was compared with that of a non-pathogenic strain of E. coli. The results showed that counts of the pathogenic strain during storage at 4 and 8°C were higher than those of the non-pathogenic strain. Turkish scientists (50) have studied the microbiological properties of labneh concentrated yoghurt stored under oil at room temperature and refrigerator temperature.
An Italian study looked into the occurrence of yeast contamination in yoghurt (51). Examination of 40 samples of fruit yoghurt with obvious signs of blowing, produced by two different firms, revealed the presence of three different species of yeast - Pichia fermentans, Torulospora delbrueckii and Claviospora lusitaniae. This is believed to be the first recorded time that these yeast species have been associated with yoghurt blowing. Several reports are associated with health-nutritional aspects of yoghurt. The first of these, from Argentina (52), gives the results of trials where mice were fed with different doses of yoghurt as part of a milk re-nutrition diet on recovery of the intestinal barrier and mucosal immune function. The results suggest that, although they were obtained with an animal model, the consumption of yoghurt by malnourished children may accelerate the restoration of gut function following intestinal malfunction.
In trials in the USA (53), the addition of three servings of yoghurt daily to the diet of 29 postmenopausal women with habitually low calcium intakes resulted in a significant reduction in the urinary excretion of N-telepeptide, a marker for bone resorption. The nutrients added with the yoghurt greatly improved overall diet quality as compared with a nutrient-poor snack diet. Somewhat inconclusive results were obtained in Italy (54) during a study of the effects of yoghurt feeding as a dietary supplement for 12 healthy, elderly people. However, significantly lower faecal clostridia counts were obtained in comparison with the controls, which suggests a beneficial effect of yoghurt feeding.
Polish scientists (55) have reported on the effects of certain factors on the properties of set-type ewes' milk yoghurt. The factors studied included different starter cultures and fat contents and their effects on overall quality, rheological and sensory properties when fresh and following storage for up to 14 days at 5°C. The same team (56) has also studied the sensory quality and physico-chemical properties of ewes' milk yoghurt made from milk with fat contents ranging from zero to six per cent. Quality parameters varied with fat content and storage time, and optimum results for sensory quality were obtained for non-fat yoghurts.
A Greek study (57) looked at the effects of frozen storage of ewes' milk on the microbiological and physicochemical properties, as well as its yoghurt-making ability. The overall quality of yoghurt made from frozen stored ewes' milk was as high as that made from fresh milk. Another Greek report (58) described a method for the detection of bovine milk in ovine yoghurt by electrophoresis of para-k-casein.
Finally, it was concluded from a study carried out in Croatia (59), that goats' milk yoghurt fermented with probiotic bacteria and fortified with 1.5 per cent inulin shows good potential as a functional food.
References
(30) Cheng, L J et al (2002) Austral J Dairy Technol 57(3)187
(31) Bhullar, Y S et al (2002) Milchwissenschaft 57(6)328
(32) Shihata, A et al (2002) Internat Dairy J 12(9)765
(33) Brennan, E M et al (2002) J Food Sci 67(7)2785
(34a) Lorenzen, P C et al (2002) Internat J Dairy Technol 55(3)152
(34b) Haque, A et al (2001) Food Hydrocolloids 15(4/6)593
(35) Vercet, A et al (2002) J Agric & Food Chem 50(21)6165
(36) Harte, F et al (2002) J Food Sci 67(6)2245
(37) Meester, R 2002) Food Ingred & Anal Internat 24(1)12
(38) Jaros, D et al (2002) Milschwissenschaft 57(8)447
(39) Carson, K et al (2002) J Food Sci 67(3)1224
(40) Haque, Z Z et al (2002) Food Sci & Technol Res 8(1)21
(41) Mistry, V V (2002) Lait 82(4)515
(42) Dunchenko, N I et al (2002) Moloch Promyshl No 10 p27
(43) Crittenden, R G et al (2002) Internat J Food Microbiol 80(3)217
(44) Oliveira, C A F et al (2002) Austral J Dairy Technol 57(3)192
(45) El-Sayed, E M et al (2002) Europ Food Res & Technol 215(4)298
(46) Ozer, B et al (2002) Internat J Dairy Technol 55(4)166
(47) Govaris, A et al (2002) Food Additives and Contam 19(11)1043
(48) Yague, C et al (2002) J AOAC Internat 85(5)1181
(49) Bachrouri, M et al (2002) J Food Sci 67(5)1899
(50) Say, D et al (2002) Milchwissenschaft 57(9/10)528
(51) Vallone, L et al (2001) Industrie Alimentari 40(407)1001
(52) Gauffin-Cano, P et al (2002) J Dairy Res 69(2)303
(53) Heaney, R P et al (2002) J Amer Dietet Ass 102(11)1672
(54) Canzi, E et al (2002) Lait 82(6)713
(55) Bonczar, G et al (2002) Food Chem 79(1)85
(56) Bonczar, G et al (2002) Zywnosc 9(1)109
(57) Katsiari, M C et al (2002) Food Chem 77(4)413
(58) Kaminarides, S E et al (2002) Food Chem 78(1)53
(59) Bozanic, R et al (2002) Mljekarstvo 52(2)93

This review was originally published in the August 2003 edition of Dairy Industries International

sábado, abril 10, 2004

Bacteria banish fowl bugs

by Helen R. Pilchernews@nature.com
Publicado en: BioEd Online (http://www.BioEdOnline.org)

A probiotic diet makes chickens healthier and safer to eat.

Chickens could benefit from a daily dose of friendly bacteria, researchers say.
Probiotic bugs can destroy food-poisoning bacteria inside poultry, making the birds healthier and safer to eat.
The benefits to human health of probiotics are well known. The bacteria, found in yoghurt, are thought to out-compete other gut bacteria, including those that cause food poisoning.
Probiotics are thought to have similar benefits in animals, and are already included in some agricultural feeds. But such feeds contain a slew of bacteria, says Arjan Narbad from the Institute of Food Research, Norwich, so their effects are uncertain.

Narbad and colleagues tested a single probiotic dose in the lab. The good bacterium Lactobacillus johnsonii ousted the harmful Clostridium perfringens from chicks' guts, they report in Letters in Applied Microbiology 1 .

"We have used a single strain and shown that it can be targeted to eliminate a specific pathogen," says Narbad.
Clostridium can flare up chickens, making them sickly and thin. It's also one of the top five bacterial causes of food poisoning in humans. In the United Kingdom, the bug poisons about 200 people through undercooked chicken each year.

Health food
"We also have preliminary data suggesting that Lactobacillus may be effective against Campylobacter," Narbad says. This is a much nastier bug, causing about 63,000 UK cases of food poisoning each year. Lactobacillus also has a weak effect against the sometimes-deadly gut bacterium E. coli.

Probiotics could have other benefits too. They may also increase chicken growth rate, for example, says microbiologist Anne McCartney from the University of Reading.
The probiotic bacteria are easy to give to animals, as they can be put in animal feed or drinking water, says Narbad.
They should also help to reduce the use of antibiotics in animals. Farmers are being encouraged to cut their use of antibiotics to reduce the chance of bacteria evolving resistance.
The team is now seeking other probiotic species to help combat different pathogens. They plan to test the treatments on farms to see if results are as good as they are in the lab.

1 La Ragione, R.M., La Narbad, M.J., Gasson, M.J. & Woodward, M.J.. Letters in Applied Microbiology, 28, 197 - 205, (2004).

jueves, enero 22, 2004

Microbiology: Gut reaction

Nature 427, 284 - 286 (22 January 2004); doi:10.1038/427284a

Consumers are stocking up on live yoghurts and fermented drinks that claim to improve health. But is there any science behind the marketing of these 'probiotic' products? Alison Abbott investigates.
Glenn Gibson's wife prefers him to tell dinner-party guests that he works as a painter and decorator. That's understandable, because if he talks about his real job as a researcher of gut bacteria at theUniversity of Reading, UK, the conversation all too easily turns to the source of his research material — human excrement.
For better or worse, faeces provide the best window into the microbial life of the human gut, a subject that is attracting more funding nowthan ever before. Partly in reaction to commercial claims that the bacteria in some yoghurts and other 'probiotic' products can boost health, the European Union (EU) has invested more than 15 million (US$19 million) since 1995 to research this poorly explored frontier.

As a result, a growing number of microbiologists are taking an interest in the ecology of the human gut. They are adapting tools previously developed for the study of microbes in oceans and soil to answer a range of questions. What lives in our gut? Do some natural gut microbes predispose us to diseases such as colon cancer? And can we change the make-up of our intestinal residents to improve our health?
Gibson has even built a collection of artificial guts to study our internal microbial ecology under controlled laboratory conditions (see 'Roboguts').

Hidden world
The average human intestine contains about 1.2 kilograms of bacteria plus a smattering of yeasts. So far, few of these microbes have been characterized or even identified. But this dearth of information hasn't kept companies from promoting the health value of probiotics, which contain living bacteria, and prebiotics — nutrients designed to boost populations of beneficial bacteria already living in the gut.

Probiotic dietary supplements are available in just about any form imaginable, from tubes of liquid to capsules. Some yoghurts and fermented milk drinks also promote their living contents. A typical online shop claims that its probiotic products can "strengthen the immune system, reverse the negative effects on the digestive tract of infections, antibiotics, alcohol ... treat symptoms of irritable bowel disease" and more.
Worldwide, the pro- and prebiotics market is now worth about US$6 billion.
But so far, the science behind these commercial boasts is rather limited. "There are a lot of bogus claims and vested interests," says Michael Blaut, head of gastrointestinal microbiology at the German Institute of Human Nutrition in Potsdam, and one of the researchers who helped to convince the EU to fund probiotics research.
Although some clinical trials of probiotics have suggested a benefit, Gibson adds, few of these have been sufficiently rigorous. And even when probiotics seem to work, he says, we know too little about the normal gut ecosystem to understand why.

Soon after it was established, the EU-funded network, which includes scientists from 16 countries, discovered that the gut ecosystem is much more diverse than previously thought. Microbiologists knew that their traditional techniques of isolating and cultivating individual microorganisms were not pulling out all of the species that we live with. Many gut bacteria are notoriously difficult to grow in culture — largely because they depend on the presence of other bacterial species. But few scientists had anticipated just how diverse the ecosystem would turn out to be.

To begin to quantify the diversity, gut researchers borrowed a method from soil and ocean microbiologists that relies on comparisons of the gene for a portion of the ribosome — the cellular machine that manufactures new proteins — known as 16S. The ribosome is so fundamental to the workings of the cell that it has changed little during evolution. That makes it easy to extract the 16S genes from all microorganisms in a single faecal sample using the DNA-amplifying polymerase chain reaction. By looking for subtle differences between the sequences of these genes, microbiologists can gauge the number of different species present in the sample.

One surprise was that no two people have quite the same complement of bacteria. In unpublished work, molecular biologist Joël Doré of the INRA, the French agricultural research agency in Jouy-en-Josas, near Paris, has so far analysed the faeces of more than a dozen healthy adults and found the contents of each to be quite different. Although thousands of microbes can live in the gut, each person has only about 100 different species. "There is remarkably little overlap in the gut bacterial species between individuals," he says.

This is partly because of the haphazard way in which the bacteria arrive. Our guts start off in the womb completely sterile, but they are rapidly colonized with vaginal and faecal bacteria during birth.
Microorganisms from food and other environmental sources contribute to the mix during the first months of life. By the age of two at the latest, the average human gut hosts its full complement of microbial species, mixed and matched from a dozen or so dominant groups of bacteria and a longer list of rarer bacteria and yeasts.

From this point on, little changes until old age — a person's microbial complement seems to remain stable throughout adulthood, Doré says.
But he has found that the faeces of people over 60 contain a much larger number of different bacteria than younger people. He suspects that the weakening barrier to new species may help explain why the elderly are more susceptible to gut infections and certain forms of cancer.

Colonic closed shop
The basis of the microbial stability that persists throughout most of our lives is still poorly understood, but is probably related to nutrient supply. By the time an infant is two years old, resident bacteria have monopolized every source of nutrients in the gut. They have also become interdependent, supplying nutrients to each other — one cell's waste is another's food. With all the nutrients accounted for, newcomers may find it hard to gain a toehold.

The stability of this ecosystem benefits not only the gut microbes, but also the human host. It prevents pathogenic bacteria, such as the various species of Salmonella that cause food poisoning, from taking up long-term residence. But it also means that probiotics cannot permanently change the make-up of the gut — they must be taken daily to have any effect.

What are the possible benefits? Individual species of bacteria are informally classified on a sliding scale of 'goodness' and 'badness'.
Collectively, gut bacteria aid digestion by breaking down tough fibres, enzymes and other proteins. In addition, 'good' bacteria, such as species of Lactobacillus, Bifidobacterium and Eubacterium, are involved in fermentation reactions that produce organic acids that can be absorbed into the body and used as an energy source. 'Bad' bacteria, such as some members of the genus Clostridium, generate as by-products compounds including nitrosamines and cresols, which are possible carcinogens.

Commercial probiotic strains are, of course, 'good' bacteria. The probiotic milk products, yoghurts and capsules on the market generally contain Lactobacillus and Bifidobacterium. Most studies of their efficacy have been poorly controlled and have produced contradictory results, says Gibson. But a handful of well-designed clinical trials indicates that some such bacteria may help ameliorate diarrhoea1-3 and some types
of inflammatory bowel disease4, 5.
Less well documented are the claims for beneficial stimulation of the immune system. The gut, with its massive blood supply, is the immune system's primary contact with the outside world, and gut bacteria seem to play a role in teaching the immune system to differentiate between dangerous invaders and non-hostile challenges.
Although some studies suggest that probiotics can affect features of the immune system, few have shown that these changes are beneficial to health.
A notable exception is a long-term study supported by the Finnish Academy of Sciences, in which pregnant women from families prone to allergies ate Lactobacillus rhamnosus daily. After delivery, the bacteria were given daily to the babies for the first six months of their lives.

The treated infants were much less prone to allergic reactions such as eczema than controls who did not get the bacteria6, 7. Erika Isolauri, an immunologist at th University of Turku who led the study, is now trying to determine how the treatment works. She suspects that the probiotics shift the balance between pro- and anti-inflammatory factors in the developing gut.

Friend or foe?
Other studies to assess the health benefits of probiotics are under way. With funding from the EU, for example, Doré is setting out to test a combination of Bifidobacterium animalis and a type of prebiotic sugar known as FOS on the gut ecosystems of young and old people in France, Germany, Sweden and Italy. "We are testing faecal samples to see whether the level of Bifidobacterium really does rise with this treatment, as would be expected," he says. His team will also assess how the levels of toxic and potentially carcinogenic compounds in the gut rise and fall with treatment by exposing cell cultures to extracts from the subjects' faeces. The researchers hope to determine whether suppressing 'bad' bacteria with pre- and probiotics might protect against colon cancer.

Francisco Guarner, a gastroenterologist at the Vall d'Hebron Hospital in Barcelona, Spain, is helping to organize an EU-backed clinical study involving 360 patients chronically suffering from one of two types of inflammatory bowel disease — ulcerative colitis or Crohn's disease — at centres in Ireland, Spain, Finland and France. The patients, all in remission, receive either Lactobacillus salivarius or Bifidobacterium infantis, two species that reduce gut inflammation in lab animals. The researchers then test the patients' saliva for marker molecules associated with inflammation. "Animal studies show that inflammatory disorders of the bowel may be helped by making the gut microbes less aggressive," says Guarner. He hopes that the probiotics will extend the patients' remission so they can reduce their reliance on immunosuppressive drugs, which have severe side effects.
Outside the EU network, Gibson is running trials at six British centres using Lactobacillus plantarum together with a second type of prebiotic sugar called GOS in various kinds of inflammatory bowel disease.

Gibson's hypothesis is that the yeast Candida causes the symptoms, and he hopes that the probiotics will outcompete its growth. In a separate study, he is testing his hypothesis that certain 'bad' bacteria contribute to ulcerative colitis by generating toxic sulphur compounds such hydrogen sulphide, which smells of rotten eggs. He is giving patients FOS and GOS to stimulate the growth of competing 'good' bacteria to see whether this eases the symptoms.
Microbes on trial
In the next few years, these and other studies will help to determine how beneficial probiotics actually are. In the meantime, other salient questions are being addressed. Can we, for example, assume that probiotics are safe? One potential problem is that many probiotic strains have genes that allow them to resist antibiotics, which they might pass on to pathogenic bacteria. To address these concerns, Herman Goossens of the University of Antwerp in Belgium has acquired more than 200 commercial probiotic strains — the world's largest collection. He is systematically analysing them for their potential to transfer antibiotic resistance genes, and is also testing for any direct toxic effects that they may have.

Some experts believe that another important step will be to read the genomic sequence of every species of microbe that can colonize the human gut. They argue that a complete genomic databank would make it much easier to select species for specific probiotic effects.

To that end, the Defense Advanced Research Projects Agency, a research arm of the US military, is sponsoring a project to read all the genomes in the gut ecosystem with the same 'shotgun' method used for the privately funded effort to sequence the human genome. This approach avoids the need to separate out individual organisms.

Instead, fragments of all the genomes are read off together. Computer algorithms then reassemble the fragments on the basis of overlapping sequences into complete genomes. "It's possible to conceive of doing this because the cost of sequencing has come right down," says Claire Fraser, director of The Institute for Genomic Research in Rockville, Maryland, where the work will be done.

Even if probiotics and prebiotics prove to have only modest health benefits, some scientists are considering the possibility of souping them up with genetic engineering. Many proponents of probiotics reject this idea, saying that it would be too hard to convince the public to eat live, genetically modified bacteria. But among the traits that would be useful to engineer are the ability to survive the acid environment of the stomach, a bit of 'stickiness' to help bacteria adhere to the gut lining, and so take residence for longer, and the ability to produce organic acids. Bacteria might even be engineered to deliver drugs, vitamins or vaccines8, 9.

There is already evidence that some bacteria can serve as efficient delivery vehicles. For example, Lothar Steidler of Ghent University in Belgium and his colleagues have shown that Lactococcus lactis genetically modified to secrete the anti -inflammatory molecule interleukin-10 can reduce colitis in mice10. A version for humans has also been developed that includes safety features to prevent the escape of the inserted gene into the environment11. A small clinical trial of this microbe is planned in Amsterdam, marking the first use of a genetically engineered bacterium as a therapeutic agent.

Unfortunately for the scientists studying probiotics, the only way forward is to delve into more human waste. Doré says he recently felt a pang of regret over that fact on a trip to visit some oceanographer friends in Marseille. "I looked out into the Mediterranean and thought:
'I'm obviously working on the wrong ecosystem'," he sighs. But the scientific challenges presented by gut bacteria are interesting enough to keep him going, he says. "It makes up for the unpleasantness."

ALISON ABBOTT
Alison Abbott is Nature's senior European correspondent.
References
1. Guandalini, S. et al. J. Pediatr. Gastroenterol. Nutr. 30, 54–60
(2000). Article PubMed ISI ChemPort
2. D'Souza, A. L., Rajkumar, C., Cooke, J. & Bulpitt, C. J. Br. Med. J. 324,
1361–1366 (2002). Article
3. Cremonini, F. et al. Aliment. Pharmacol. Ther. 16, 1461–1467
(2002). Article PubMed ISI ChemPort
4. Rembacken, B. J., Snelling, A. M., Hawkey, P. M. Chalmers, D. M. & Axon,
A. T. R. Lancet 354, 635–639 (1999). Article PubMed ISI ChemPort
5. Gionchetti, P. et al. Gastroenterology 119, 305–309
(2000). PubMed ISI ChemPort
6. Kalliomäki, M. et al. Lancet 357, 1076–1079
(2001). Article PubMed ISI ChemPort
7. Kalliomäki, M., Salminen, S., Poussa, T., Arvilommi, H. & Isolauri, E. Lancet
361, 1869–1871 (2003). Article PubMed ISI
8. Seegers, J. F. M. L. Trends Biotechnol. 20, 508–515
(2002). Article PubMed ISI ChemPort
9. Wood, B. J. B. & Warner, P. J. (eds) in The Lactic Acid Bacteria Vol. 3, 261–
290 (Kluwer Academic, New York, 2003).
10. Steidler, L. et al. Science 289, 1352–1355
(2000). Article PubMed ISI ChemPort
11. Steidler, L. et al. Nature Biotechnol. 21, 785–789
(2003). Article PubMed ISI ChemPort

viernes, noviembre 14, 2003

Microflora in water kefir grains

Foodinfo Online FSTA Reports -->13 November 2003

Water kefir grains are a unique starter culture community commonly used to produce home-made sparkling acidic beverages with low-alcohol content.
The white to grey coloured, irregularly shaped grains comprise a backbone of a polysaccharide matrix such as dextran. The microflora of water kefir grains differs significantly from that of dairy kefir grains, which, unlike water kefir grains, have been widely studied. The grains can be simply inoculated under non-sterile conditions using sucrose-containing tap water in the presence of dried figs. They are also known as Tibi grains, sugary kefir grains, gingerbeer plants or Californian bees.
These different grains are all thought to have a similar complex microbial community comprising yeasts and lactic acid bacteria. The addition of figs is essential for the optimal fermentation and production of lactic acid and acetic acid. Figs also contain growth-promoting substances, which can be extracted with cold water. Water kefir grains utilize a nutritionally simple environment compared with the complex milk medium for dairy kefir grains. It is therefore of interest to compare the microflora of these two types of kefir grains.
In a study by Neve and Heller,1 the composition of the microflora of water kefir grains, obtained from a domestic household, was analysed. The diversity and distribution of the microbial population of the grains were also studied by scanning electron microscopy.
Water kefir grains were found to comprise a complex biofilm of yeasts and bacteria of various shapes on the grains surfaces embedded in the dextran matrix. There were high numbers of bacterial cocci in water kefir grains, compared with the scarcity reported in dairy kefir grains. Both types had a predominance of specific yeast populations.
---------------------------------------------------------------------------------
1 Neve, H; Heller, KJ (2003).
The microflora of water kefir: a glance by scanning electron microscopy.
Kieler Milchwirtschaftliche Forschungsberichte 54 (4) 337-349.
AN: 2003-07-Hs1624
TI:
The microflora of water kefir: a glance by scanning electron microscopy.
DA:
5-Jul-2003
DT:
Journal Article
AU:
Neve, H.; Heller, K. J.
PY:
2002
AD:
Inst. for Microbiol., Fed. Dairy Res. Cent., PO Box 6069, D-24121 Kiel, Germany
SO:
Kieler Milchwirtschaftliche Forschungsberichte 54 (4) 337–349
RF:
32 ref.
LA:
English with French, German summaries
SN:
0023-1347
AB:
Water kefir grains comprise a unique starter culture community used for production of home-made sparkling acidic beverages. Composition of water kefir grains obtained from a private household and preserved in the laboratory for several years was investigated by SEM. A complex and tightly packed biofilm was observed on the exterior of the grains, while the interior mainly comprised unstructured (dextran) material. Microflora was dominated by lemon-shaped or long filamentous yeast cells growing in close association with bacterial cocci and short or long rod shaped bacteria (lactobacilli, responsible for polymer production). Cocci grew preferentially on the surfaces of the yeast cells, while the rod-shaped bacteria were mainly found between the yeast cells. Results are discussed in relation to microflora of dairy kefir grains.
SC:
Alcoholic and non-alcoholic beverages
KW: BEVERAGES; ELECTRON MICROSCOPY; FERMENTED MILK; KEFIR GRAINS; MICROFLORA; MICROORGANISMS; SEM; STRUCTURE

sábado, julio 19, 2003

Bacteria and us
FoodInfo Online Features -->18 July 2003
Svetlana Rodgers Senior Lecturer, School of Management, College of Law and Business, University of Western Sydney, Campbelltown campus, Building 17, Locked Bag 1797, Penrith South DC NSW 1797 Australia.


Hygiene and cleanliness are undoubtedly embedded in our consciousness.
Our supermarkets are full of antibacterial detergents, sanitisers, toothpastes, sprays, creams and lotions, while the food we eat is often over-processed and devoid of natural bacteria. Even salad vegetables are washed in a sanitiser.
Psychologically, the dislike of bacteria most likely originates from the fear of infection, which has followed humankind throughout its history.
In the Middle Ages, for example, the poor quality of the water meant that it was safer to drink wine. From a practical perspective, modern food companies follow strict hygiene rules so that they comply with food legislation requirements, with many resources being utilised so that they may adhere to such guidelines.
Our frequent preoccupation with hygiene and cleanliness carries a price not only to the environment, but also to our health. Throughout much of our evolution, humans have been bombarded with dirt and germs - removal of which from our surroundings also reduces stimulation of the human immune system, which, as a consequence, would function below optimum if man lived in such a barren environment.
Scientists believe that children raised in less hygienic conditions are less likely as adults to develop asthma, allergies, diabetes, rheumatoid arthritis and other immunity-linked disorders. In 1910, in his book, The Prolongation of Life, the founder of the theory of 'probiotic' or beneficial bacteria, Russian scientist and Nobel Prize Laureate Ilya Metchnikoff, said 'a reader who has little knowledge of such matters may be surprised by my recommendation to absorb large quantities of microbes, as the general belief is that microbes are all harmful. This belief, however, is erroneous'. Since then, it has been found that probiotic bacteria can reduce the risk of colon cancer, lower cholesterol, increase immunity, and can even offer protection from diarrhoea.
We carry about 8 kg of indigenous bacteria in our gut, the quality of which is important to our health. The addition of probiotic bacteria to fermented products has become common today.
In Russia, yoghurt made using the 'strong' bacteria taken from the guts of cosmonauts are a marketing attraction, while in the livestock industry, pathogen-fighting bacteria can replace the use of antibiotics.
Probiotic bacteria can even be added to women's hygiene products to exclude bacteria that can cause debilitating infections, premature births or infection of newborn infants.
Harmless bacteria can not only improve our health and immunity, but can also exclude food poisoning bacteria in foods. So-called lactic acid bacteria are present in high numbers in products such as yoghurt, fermented vegetables and sausages. This explains why fermented products have an excellent food safety record.
In 1995, a leading scientist in food microbiology, James Jay, wrote an article called 'Foods with low numbers of microorganisms may not be the safest foods'. He argued that, with improvements in cleaning/sanitising, not enough harmless background organisms were left to prevent proliferation of food poisoning bacteria. Surprisingly, there are very few commercial applications of so-called 'protective' cultures in non-fermented foods.
The Wisconsin process for cured bacon is one of these applications and employs addition of sucrose and lactic acid bacteria to prevent botulism in bacon, together with low concentrations of nitrite. Botulism is also a potential risk for refrigerated minimally processed foods, such as packaged cook-chill meals used in catering and retail. At the Centre for Advanced Food Research at the University of Western Sydney, we have developed a method using lactic acid bacteria for the prevention of botulinal toxin formation in cook-chill meals. As with the majority of microorganisms, these protective cultures are dormant when the product is stored under the correct temperature and 'switch on' to fight food poisoning bacteria only when temperature abuse takes place. Although the cultures may be visible in clear products, they go unnoticed in thick soups or casserole-style products.
In a recent trial, a sensory evaluation panel was unable to distinguish between seafood chowder, vegetable curry and chicken casserole with and without culture added. The biggest technological challenge now is to develop a method to protect these cultures during heating. If a product is cooked and then aseptically/hygienically packaged or stored under vacuum in Greenvac-type containers, the cultures can be incorporated directly. Extended shelf life cook-chill technology, however, is a modern development, which requires more sophisticated preservation methods.
In addition, the risks of food poisoning are increased through intensive farming practices, extensive transportation, the emergence of more resistant bacteria and an ageing population. Protective cultures offer temperature-responsive, natural preservation, and also bring some bacteria back into our lives.

For more information contact Svetlana Rodgers, senior lecturer, whose research led to the patent application "Preserving with Lactic Acid Bacteria" PCT/AU01/01549